| Similar Articles |
|---|
 |
BusinessWeek
April 19, 2004
John Carey |
Drugs: Is Something Rotten? The author of The $800 million pill recounts how many drugs were created with government funding -- then were sold to consumers at sky-high prices. And he proves that Big Pharma need not require $800 million to develop an important new drug, as it insists.   |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
May 11, 2010
Ryan McBride |
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. |
Fast Company
November 2010
Elizabeth Svoboda |
The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
March 28, 2011
Brian Orelli |
Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news. |
Chemistry World
December 5, 2014
Rebecca Trager |
Tufts' $2.6bn drug development figure questioned Recent data indicating that it costs about $2.6 billion to develop and win market approval for a new prescription drug in the US has come under scrutiny. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
BusinessWeek
May 27, 2010
Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
Pharmaceutical Executive
February 1, 2011
Jill Wechsler |
The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome? |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
The Motley Fool
February 22, 2011
Ryan McBride |
Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
Reason
October 2007
Ronald Bailey |
Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest." |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease |
The Motley Fool
September 24, 2010
Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
